Wockhardt's Zaynich: The Science and Business Potential of a Promising Superbug Killer

Wockhardt's Breakthrough Antibiotic Zaynich Gains Regulatory Approval in India

Wockhardt, a Mumbai-based drugmaker, has achieved a significant milestone in its drug discovery efforts with the Central Drugs Standard Control Organisation (CDSCO) approving its novel antibiotic Zaynich for sale in India. This news triggered a rally in Wockhardt's shares, with the stock gaining as much as 11 percent in early trade on May 29, demonstrating investor optimism about the potential breakthrough product.

The optimism surrounding Zaynich stems from its potential to address one of medicine's most pressing challenges — drug-resistant "superbugs." Zaynich is an injectable drug that combines cefepime, an existing antibiotic, with zidebactam, a new molecule designed to enhance its effectiveness. Cefepime works by killing bacteria, while zidebactam helps protect it from being neutralised by bacterial defence mechanisms.

The rise of multi-drug resistant (MDR) or extreme drug-resistant (XDR) infections poses a significant threat to public health. These infections are common in hospitals and can lead to serious conditions such as bloodstream infections, severe pneumonia, or complicated urinary tract infections. Traditionally, doctors rely on last-resort antibiotics like carbapenems, including meropenem, but resistance to these drugs is rising, leaving few treatment options. Zaynich is specifically designed to tackle these hard-to-treat infections where existing therapies fail.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

What sets Zaynich apart scientifically is its novel mechanism. Bacteria often produce enzymes, particularly beta-lactamases, that destroy antibiotics before they can work. Zidebactam acts as a "shield-breaker" by blocking these enzymes and allowing cefepime to remain active. This mechanism is particularly effective against metallo-beta-lactamase (MBL) resistance, one of the toughest forms of resistance seen in India's hospitals.

Clinical data backs the promise of Zaynich. In global Phase 3 trials, the drug showed an 89 percent clinical cure rate compared with 68.4 percent for meropenem, the current standard of care. In high-risk patients, the gap was even wider, with Zaynich delivering an 89 percent response rate versus just 44 percent for meropenem. The company has also reported success rates of over 95 percent in compassionate use cases involving critically ill patients who had no other treatment options.

The regulatory approval in India allows Wockhardt to market Zaynich for complicated urinary tract infections and associated bloodstream infections in adults. Globally, the drug is progressing through advanced regulatory pathways, with the US Food and Drug Administration (FDA) granting it "fast track and qualified infectious disease product" designations. Applications in Europe are under active review, highlighting the importance of the therapy.

For Wockhardt, Zaynich could be transformative. The regulatory approvals are validation of the company's two-and-half decades of drug discovery and steadfast approach of its founder and chairperson Dr Habil Khorakiwala. The company estimates a $7 billion global market and a large patient pool across regions, with a domestic opportunity of 1.1 million cases annually.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline